Document 0149
 DOCN  M9550149
 TI    Current and potential treatment of tuberculosis.
 DT    9505
 AU    Houston S; Fanning A; Department of Medicine, University of Alberta,
       Edmonton, Canada.
 SO    Drugs. 1994 Nov;48(5):689-708. Unique Identifier : AIDSLINE MED/95136883
 AB    A recent resurgence of interest in tuberculosis as a global health
       problem has accompanied the resurgence of tuberculosis in both
       industrialised and developing countries. It has also been demonstrated
       recently that tuberculosis treatment and control is one of the most cost
       effective of all medical interventions. The human immunodeficiency virus
       (HIV) epidemic and increasing resistance to antituberculous drugs
       complicate our response to the problem of tuberculosis. Chemotherapy
       with currently available agents is highly effective, not only in
       pulmonary tuberculosis in adults, but also in extrapulmonary disease,
       and in disease in children and even patients with concomitant HIV
       infection. Short course chemotherapy and intermittent therapy are as
       effective as older regimens. Measures, including directly observed
       therapy, to maximise compliance with therapy, are of utmost importance.
       An efficient programme which assures compliance with effective
       antituberculosis chemotherapy should be a priority for health spending
       even in those countries with fewest resources.
 DE    Animal  Antitubercular Agents/*THERAPEUTIC USE  Human
       Tuberculosis/*DRUG THERAPY/EPIDEMIOLOGY/MICROBIOLOGY  JOURNAL ARTICLE
       REVIEW  REVIEW, ACADEMIC

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).